Valuation: Vaxart, Inc.

Market Cap 122M 105M 97.98M 89.5M 169M 11.63B 171M 1.16B 450M 5.87B 458M 448M 19.44B P/E 2026 *
-3.14x
P/E 2027 * -0.59x
Enterprise Value 122M 105M 97.98M 89.5M 169M 11.63B 171M 1.16B 450M 5.87B 458M 448M 19.44B EV / Sales 2026 *
1.03x
EV / Sales 2027 * 51.9x
Free-Float
98.56%
Yield 2026 *
-
Yield 2027 * -
1 day+0.63%
1 week+21.98%
Current month+11.83%
1 month+22.00%
3 months-6.34%
6 months-16.11%
Current year+74.34%
1 week 0.49
Extreme 0.4901
0.62
1 month 0.44
Extreme 0.44
0.64
Current year 0.34
Extreme 0.3434
0.84
1 year 0.3
Extreme 0.305
0.84
3 years 0.26
Extreme 0.2606
1.54
5 years 0.26
Extreme 0.2606
9.4
10 years 0.25
Extreme 0.2543
24.9
Manager TitleAgeSince
Chief Executive Officer 60 18/03/2024
Chief Tech/Sci/R&D Officer 59 01/03/2024
Director of Finance/CFO - 19/05/2025
Director TitleAgeSince
Director/Board Member 68 21/04/2021
Director/Board Member 76 04/08/2022
Director/Board Member 79 01/01/2022
Date Insider Type Main position Quantity % Market Cap.
7/16/26 A Free

Director

118,100 0.0488%
7/16/26 A Free

Director

118,100 0.0488%
7/16/26 A Free

Director

118,100 0.0488%
Change 5-day change 1-year change 3-year change Capi.($)
+0.63%+21.98%+70.98%-23.29% 122M
+3.31%-3.70%+61.03%+103.64% 71.35B
+2.00%+1.98%+49.52%+90.59% 64.17B
+1.09%+22.96%+8.55%-3.03% 28.65B
-0.07%-3.56%-3.45%+467.26% 27.06B
-2.49%+6.26%+56.04%+12.49% 27.33B
-0.41%+4.37%+39.47%-14.65% 20.47B
+1.02%+6.43%+269.42%+420.34% 19.36B
0.00%0.00%+7.80%+542.33% 15.96B
+3.98%+6.78%+49.66%+157.94% 14.05B
Average +0.84%+4.02%+60.90%+175.36% 28.85B
Weighted average by Cap. +1.29%+3.31%+55.70%+155.33%

Financials

2026 *2027 *
Net sales 119M 102M 95.23M 86.98M 164M 11.31B 166M 1.12B 437M 5.7B 445M 436M 18.89B 2.35M 2.01M 1.89M 1.72M 3.25M 224M 3.28M 22.26M 8.66M 113M 8.82M 8.63M 374M
Net income -47.2M -40.45M -37.9M -34.62M -65.33M -4.5B -65.98M -447M -174M -2.27B -177M -173M -7.52B -222M -190M -178M -163M -307M -21.12B -310M -2.1B -817M -10.66B -832M -814M -35.3B
Net Debt - -
Logo Vaxart, Inc.
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.
Employees
65
Date Price Change Volume
25/08/26 $0.5025 +0.40% 238,924
24/08/26 $0.5005 -2.82% 363,825
21/08/26 $0.5150 -0.90% 358,873
20/08/26 $0.5197 +4.41% 299,005
19/08/26 $0.4978 +0.54% 358,609
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.5025USD
Average target price
3.333USD
Spread / Average Target
+563.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VXRT Stock